BRPI0409895A - métodos para cultivar células imortalizadas pelas seqüências e1 de adenovìrus e para produzir um produto em células imortalizadas pelas seqüências e1 de adenovìrus, e, cultura de células imortalizadas pelas seqüências e1 de adenovìrus - Google Patents

métodos para cultivar células imortalizadas pelas seqüências e1 de adenovìrus e para produzir um produto em células imortalizadas pelas seqüências e1 de adenovìrus, e, cultura de células imortalizadas pelas seqüências e1 de adenovìrus

Info

Publication number
BRPI0409895A
BRPI0409895A BRPI0409895-1A BRPI0409895A BRPI0409895A BR PI0409895 A BRPI0409895 A BR PI0409895A BR PI0409895 A BRPI0409895 A BR PI0409895A BR PI0409895 A BRPI0409895 A BR PI0409895A
Authority
BR
Brazil
Prior art keywords
adenovirus
sequences
cells immortalized
culturing cells
cells
Prior art date
Application number
BRPI0409895-1A
Other languages
English (en)
Inventor
Christopher Adam Yallop
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of BRPI0409895A publication Critical patent/BRPI0409895A/pt
Publication of BRPI0409895B1 publication Critical patent/BRPI0409895B1/pt
Publication of BRPI0409895B8 publication Critical patent/BRPI0409895B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/33—Insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"MéTODOS PARA CULTIVAR CéLULAS IMORTALIZADAS PELAS SEQüêNCIAS E1 DE ADENOVìRUS E PARA PRODUZIR UM PRODUTO EM CéLULAS IMORTALIZADAS PELAS SEQüêNCIAS E1 DE ADENOVìRUS, E, CULTURA DE CéLULAS IMORTALIZADAS PELAS SEQUêNCIAS E1 DE ADENOVìRUS". A invenção proporciona processos para cultivar células derivadas de células embriónicas de retinoblasto por seqüências E1 de adenovírus, preferivelmente células PER.C6¬ TM¬, para melhorar os rendimentos de produto de tais células. São proporcionadas estratégias de alimentação para tais células e culturas com densidades celulares muito altas, resultando em rendimentos elevados de produtos, tais como anticorpos recombinantes.
BRPI0409895A 2003-05-09 2004-05-06 método de cultura de células derivadas de células per.c6 capazes de crescer em suspensão para aumentar o rendimento de produto das referidas células BRPI0409895B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP0350155 2003-05-09
EP0350390 2003-09-01
EP0350940 2003-12-04
EP2004050061 2004-01-30
PCT/EP2004/050724 WO2004099396A1 (en) 2003-05-09 2004-05-06 Cultures of e1-immortalized cells and processes for culturing the same to increase product yields therefrom

Publications (3)

Publication Number Publication Date
BRPI0409895A true BRPI0409895A (pt) 2006-05-23
BRPI0409895B1 BRPI0409895B1 (pt) 2018-09-18
BRPI0409895B8 BRPI0409895B8 (pt) 2021-05-25

Family

ID=33437116

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409895A BRPI0409895B8 (pt) 2003-05-09 2004-05-06 método de cultura de células derivadas de células per.c6 capazes de crescer em suspensão para aumentar o rendimento de produto das referidas células

Country Status (15)

Country Link
US (4) US7291484B2 (pt)
EP (1) EP1623023B1 (pt)
JP (1) JP4865539B2 (pt)
KR (1) KR101183770B1 (pt)
CN (2) CN100383238C (pt)
AT (1) ATE414144T1 (pt)
AU (1) AU2004236440B2 (pt)
BR (1) BRPI0409895B8 (pt)
CA (1) CA2520891C (pt)
DE (1) DE602004017709D1 (pt)
DK (1) DK1623023T3 (pt)
EA (1) EA008670B1 (pt)
IL (2) IL171680A (pt)
NZ (1) NZ542585A (pt)
WO (1) WO2004099396A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783980B2 (en) * 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
DE69633565T3 (de) 1995-06-15 2013-01-17 Crucell Holland B.V. Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US6855544B1 (en) * 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
ATE384785T1 (de) 2001-12-07 2008-02-15 Crucell Holland Bv Herstellung von viren, virusisolaten, und impfstoffen
NZ542585A (en) 2003-05-09 2007-11-30 Crucell Holland Bv Cultures of PER.C6-immortalized cells and processes for culturing the same to increase product yields therefrom
PL1720972T3 (pl) 2004-03-05 2014-06-30 Dpx Holdings Bv Proces hodowli komórek poprzez ciągłą perfuzję i zmienny przepływ styczny
US9714410B2 (en) * 2005-01-05 2017-07-25 Chugai Seiyaku Kabushiki Kaisha Cell culture method and utilization of the same
DE102005054628A1 (de) 2005-11-16 2007-05-24 Cevec Pharmaceuticals Gmbh Verfahren zur Herstellung von permanenten humanen Zelllinien
CA3028321C (en) 2006-01-23 2022-06-21 Athersys, Inc. Mapc treatment of brain injuries and diseases
EP1870450A1 (en) * 2006-06-21 2007-12-26 DSMIP Assets B.V. Process for the culturing of E1-immortalized HER cells
AU2011211462C1 (en) * 2006-07-14 2015-01-22 Dpx Holdings B.V. Improved process for the culturing of cells
FI2343362T4 (fi) 2006-07-14 2024-07-04 Patheon Holdings I B V Parannettu menetelmä solujen viljelyä varten
WO2008065372A2 (en) 2006-11-28 2008-06-05 Nautilus Biotech, S.A. Modified erythropoietin polypeptides and uses thereof for treatment
WO2008136398A1 (ja) 2007-04-26 2008-11-13 Chugai Seiyaku Kabushiki Kaisha 高濃度アミノ酸含有培地を用いた細胞の培養方法
WO2009023562A2 (en) * 2007-08-09 2009-02-19 Wyeth Use of perfusion to enhance production of fed-batch cell culture in bioreactors
CA2735790C (en) 2008-09-02 2017-02-28 Pluristem Ltd. Adherent cells from placenta tissue and use thereof in therapy
DK2421895T3 (en) 2009-04-23 2016-01-25 Crucell Holland Bv Recombinant human alpha 1-antitrypsin
HRP20140597T1 (hr) * 2009-07-16 2014-09-12 Crucell Holland B.V. Proizvodnja polio virusa u visokim titrima za proizvodnju cjepiva
WO2011045381A1 (en) 2009-10-15 2011-04-21 Crucell Holland B.V. Process for adenovirus purification from high cell density cultures
MX2012004222A (es) 2009-10-15 2012-06-08 Crucell Holland Bv Metodo para purificacion de particulas de adenovirus.
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
WO2012045769A1 (en) 2010-10-05 2012-04-12 Novo Nordisk Health Care Ag Process for protein production
US9631216B2 (en) 2011-04-29 2017-04-25 Biocon Research Limited Method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof
CN102994547B (zh) * 2011-09-08 2015-05-13 哈药集团技术中心 重组人促红素-ctp融合蛋白生产工艺及应用
WO2014054744A1 (ja) * 2012-10-03 2014-04-10 協和発酵キリン株式会社 培養液にアミノ酸を添加することによるポリペプチドの還元防止方法
SG11201601182QA (en) 2013-09-30 2016-04-28 Crucell Holland Bv Method for the clarification of high density crude cell culture harvest
DK3172317T3 (da) 2014-07-24 2019-07-22 Janssen Vaccines & Prevention Bv Fremgangsmåde til oprensning af poliovirus fra cellekulturer
RU2672318C1 (ru) * 2017-09-19 2018-11-13 Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" Способ получения моноклональных антител терапевтического назначения с помощью непрерывного культивирования клеток сно
US11774287B2 (en) 2019-05-28 2023-10-03 WuXi Biologics Ireland Limited Raman spectroscopy integrated perfusion cell culture system for monitoring and auto-controlling perfusion cell culture
CN115369069B (zh) * 2022-08-22 2023-12-19 上海健士拜生物科技有限公司 293细胞补料培养基及其制备和应用

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
FR2573436B1 (fr) 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US4835260A (en) 1987-03-20 1989-05-30 Genetics Institute, Inc. Erythropoietin composition
US5192539A (en) 1988-07-21 1993-03-09 Akzo N.V. Infectious bursal disease virus production in continuous cell lines
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
GB8900483D0 (en) 1989-01-10 1989-03-08 Celltech Ltd Recombinant dna method
DE3923963A1 (de) 1989-07-20 1991-01-31 Behringwerke Ag Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung
US5856298A (en) 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
ES2100953T3 (es) 1991-08-01 1997-07-01 Fond Nat Transfusion Sanguine Expresion en lineas linfoblastoides humanas no tumorales con un vector integrante.
US5384249A (en) 1991-12-17 1995-01-24 Kyowa Hakko Kogyo Co., Ltd. α2→3 sialyltransferase
IL110669A (en) 1993-08-17 2008-11-26 Kirin Amgen Inc Erythropoietin analogs
US5658763A (en) 1993-10-25 1997-08-19 Creative Biomolecules, Inc. Methods and compositions for high protein production from non-native DNA
US5830851A (en) 1993-11-19 1998-11-03 Affymax Technologies N.V. Methods of administering peptides that bind to the erythropoietin receptor
US5773569A (en) 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5789247A (en) 1994-04-01 1998-08-04 Ballay; Annick Expression in non-tumoral human lymphoblastoid lines with an integrative vector
US5610043A (en) 1994-04-28 1997-03-11 The United States Of America As Represented By The Department Of Health And Human Services Human prostatic cell lines immortalized by adenovirus 12-simian virus 40 (AD12/SV40) hybrid virus
US5767078A (en) 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
US6265212B1 (en) 1995-06-15 2001-07-24 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
DE69633565T3 (de) 1995-06-15 2013-01-17 Crucell Holland B.V. Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie
US5989805A (en) 1995-10-27 1999-11-23 Board Of Trustees Operating Michigan State University Immortal avian cell line to grow avian and animal viruses to produce vaccines
AU709831B2 (en) 1995-11-13 1999-09-09 Takara Bio Inc. Method for gene transfer into target cells with retrovirus
US5681597A (en) * 1996-02-06 1997-10-28 Liquid Container L.P. Vacuum conveyor picker for blow bottle container
US5856292A (en) 1996-04-08 1999-01-05 Colgate Palmolive Company Light duty liquid cleaning compositions
US5835382A (en) 1996-04-26 1998-11-10 The Scripps Research Institute Small molecule mimetics of erythropoietin
CA2268001A1 (en) 1996-10-25 1998-05-07 G.D. Searle & Co. Circularly permuted erythropoietin receptor agonists
US7732129B1 (en) * 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
CA2283253A1 (en) 1997-03-04 1998-09-11 Baxter International Inc. Adenovirus e1-complementing cell lines
CA2221819A1 (en) 1997-03-27 1998-09-27 Thomas A. Gigliatti Insect expression vectors
ATE290091T1 (de) 1997-03-27 2005-03-15 Univ British Columbia Insekten-expressionsvektoren
US5997128A (en) * 1997-05-30 1999-12-07 Hewlett-Packard Company Translational service station for imaging inkjet printheads
ES2273434T3 (es) 1997-07-23 2007-05-01 Roche Diagnostics Gmbh Obtencion de la eritropoyetina mediante activacion genica endogena.
AU744086B2 (en) 1997-12-03 2002-02-14 Roche Diagnostics Gmbh Erythropoietin with high specific activity
US6670188B1 (en) 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
CA2331154A1 (en) 1998-06-16 1999-12-23 Human Genome Sciences, Inc. Polypeptides having sequence identity with acid labile subunit of insulin-like growth factor
TR200103785T2 (tr) 1999-04-13 2002-06-21 The Kenneth S. Warren Institute, Inc. Uyarılabilir doku işlevinin periferik olarak uygulanan eritropoietin vasıtasıyla düzenlenmesi
WO2003048197A1 (en) 2001-12-07 2003-06-12 Crucell Holland B.V. Production and of viruses, viral isolates and vaccines
ES2378272T3 (es) * 1999-04-15 2012-04-10 Crucell Holland B.V. Producción de proteína recombinante en una célula humana
US7297680B2 (en) * 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US20050164386A1 (en) 1999-04-15 2005-07-28 Uytdehaag Alphonsus G. Overexpression of enzymes involved in post-translational protein modifications in human cells
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
CA2368797C (en) 1999-04-26 2010-08-17 Genentech, Inc. Cell culture process
US6215499B1 (en) * 1999-05-06 2001-04-10 Phillips Petroleum Company Method and apparatus for interactive curved surface seismic interpretation and visualization
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6558948B1 (en) 1999-11-23 2003-05-06 Stefan Kochanek Permanent amniocytic cell line, its production and use for the production of gene transfer vectors
EP1103610A1 (en) * 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
EP1184458A1 (en) 2000-08-28 2002-03-06 U-BISys B.V. Differentially expressed CD46 epitopes, proteinaceous molecules capable of binding thereto, and uses thereof
PA8536201A1 (es) 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
US20030087372A1 (en) * 2001-06-13 2003-05-08 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
US7473767B2 (en) 2001-07-03 2009-01-06 The Institute For Systems Biology Methods for detection and quantification of analytes in complex mixtures
EP2428570B1 (en) * 2001-09-28 2018-05-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Microrna molecules
ATE384785T1 (de) 2001-12-07 2008-02-15 Crucell Holland Bv Herstellung von viren, virusisolaten, und impfstoffen
DK1456238T3 (da) 2001-12-17 2008-08-18 Crucell Holland Bv Produktion af F(ab')2-fragmenter i pattedyrceller
CA2524569C (en) * 2002-05-03 2013-10-22 Duke University A method of regulating gene expression
MXPA05000063A (es) 2002-07-01 2005-04-08 Kenneth S Warren Inst Inc Citocinas recombinantes protectoras de tejido y acidos nucleicos que las codifican para la proteccion, restauracion y mejora de celulas, tejidos y organos respondedores.
ATE522130T1 (de) * 2002-07-19 2011-09-15 Univ South Carolina Zusammensetzungen und verfahren zur modulation der genexpression in pflanzen
US8524477B2 (en) 2002-10-29 2013-09-03 Crucell Holland B.V. Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
TWI328614B (en) * 2002-12-23 2010-08-11 Bristol Myers Squibb Co Product quality enhancement in mammalian cell culture processes for protein production
NZ542585A (en) * 2003-05-09 2007-11-30 Crucell Holland Bv Cultures of PER.C6-immortalized cells and processes for culturing the same to increase product yields therefrom
US20050144669A1 (en) * 2003-07-01 2005-06-30 Whitehead Institute For Biomedical Research MicroRNAs in plants
WO2005035769A2 (en) * 2003-10-09 2005-04-21 E. I. Du Pont De Nemours And Company Gene silencing by using micro-rna molecules
US7642078B2 (en) 2005-12-28 2010-01-05 Crucell Holland B.V. Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
WO2008059041A2 (en) 2006-11-16 2008-05-22 Crucell Holland B.V. Complementation of factor xi deficiency by factor v mutants

Also Published As

Publication number Publication date
US7291484B2 (en) 2007-11-06
US20100311160A1 (en) 2010-12-09
AU2004236440A1 (en) 2004-11-18
CA2520891A1 (en) 2004-11-18
NZ542585A (en) 2007-11-30
US7608431B2 (en) 2009-10-27
HK1080115A1 (en) 2006-04-21
DE602004017709D1 (de) 2008-12-24
US8008043B2 (en) 2011-08-30
EP1623023B1 (en) 2008-11-12
CA2520891C (en) 2014-07-08
EA008670B1 (ru) 2007-06-29
CN101328473B (zh) 2012-05-02
DK1623023T3 (da) 2009-03-02
WO2004099396A1 (en) 2004-11-18
KR101183770B1 (ko) 2012-09-17
IL171680A (en) 2010-05-31
JP4865539B2 (ja) 2012-02-01
EP1623023A1 (en) 2006-02-08
CN101328473A (zh) 2008-12-24
BRPI0409895B8 (pt) 2021-05-25
KR20060003081A (ko) 2006-01-09
ATE414144T1 (de) 2008-11-15
EA200501774A1 (ru) 2006-04-28
JP2006525800A (ja) 2006-11-16
AU2004236440B2 (en) 2008-10-09
US20060240513A1 (en) 2006-10-26
BRPI0409895B1 (pt) 2018-09-18
US20070031932A1 (en) 2007-02-08
US20060121611A1 (en) 2006-06-08
IL198861A (en) 2011-12-29
CN1784489A (zh) 2006-06-07
CN100383238C (zh) 2008-04-23

Similar Documents

Publication Publication Date Title
DK1623023T3 (da) Kulturer af E1-immortaliserede celler og fremgangsmåder til dyrkning deraf til forögelse af produktudbytter derfra
MX2009011363A (es) Metodo de produccion de proteinas utilizando compuestos anti-senectud.
TW200736397A (en) Method of protein production using anti-senescence compounds
DK1576182T4 (da) Produktkvalitetsforbedring ved fremgangsmåde med dyrkning af pattedyreceller til proteinfremstilling
WO2011134919A3 (en) Cho cells cultivation process 0
CY1118734T1 (el) Μεθοδοι παρασκευης γλυκοπρωτεϊνων σε κυτταροκαλλιεργειες θηλαστικου χρησιμοποιωντας γλυκοκορτικοειδη
NO20072719L (no) Serumfritt cellekulturmedium for pattedyrceller
NZ598677A (en) Production of proteins in glutamine-free cell culture media
WO2004058800A3 (en) Mammalian cell culture processes for protein production
NZ597334A (en) Cell culture improvements
BRPI0811177A2 (pt) Titulações de polipeptídeo do fator viii em culturas de células
WO2008060541A3 (en) In vitro expansion of postpartum-derived cells using microcarriers
AR053947A1 (es) Celulas huespedes recombinantes y medios para la produccion de etanol
SI1720979T1 (sl) Uporaba medija za celiäśno kulturo brez seruma zaizdelavo il-18bp pri celicah sesalcev
AR062072A1 (es) Proceso mejorado para cultivar celulas
EA201170025A1 (ru) Способы повышения жизнеспособности и продукции культуры клеток
NZ599479A (en) Improved reverse genetics methods for virus rescue
CN116200281B (zh) 一种提高β-胡萝卜素产量的解脂耶氏酵母菌株
WO2007056062A3 (en) Methods for adapting mammalian cells
BRPI0517942A (pt) meio de cultura de células isento de soro para células de mamìferos
WO2025083418A3 (en) Methods for cell culturing

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B25D Requested change of name of applicant approved
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/09/2018, OBSERVADAS AS CONDICOES LEGAIS.

B15V Prolongation of time limit allowed

Free format text: REFERENTE A PETICAO NO 870180125497 DE 03.09.2018 - RECONHECIDO O OBSTACULO ADMINISTRATIVO, DE ACORDO COM O ARTIGO 221, 2O DA LPI 9279/96 E O ARTIGO 3O DA RESOLUCAO 178/2017, SEM CONCESSAO DE PRAZO ADICIONAL, EM VIRTUDE DO ATO JA TER SIDO CUMPRIDO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/05/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.

B24D Patent annual fee: restoration after fee payment